Phase 3 Recruiting Network
This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are bei…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03418961
Sites in Washington: - Providence Regional Cancer System-Aberdeen — Aberdeen, Washington
- MultiCare Auburn Medical Center — Auburn, Washington
- Virginia Mason Bainbridge Island Medical Center — Bainbridge Island, Washington
- Overlake Medical Center — Bellevue, Washington
- PeaceHealth Saint Joseph Medical Center — Bellingham, Washington
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of vorasidenib to placebo in combination with usual treatment, temozolomide, in treating patients with newly diagnosed grade 3 astrocytoma after radiation. Temozolomide is in a class of medications …
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07215910
Sites in Washington: - Swedish Medical Center-First Hill — Seattle, Washington
Phase 3 Recruiting NIH
This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated low-grade glioma (LGG) that does not have…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04166409
Sites in Washington: - Seattle Children's Hospital — Seattle, Washington
- Providence Sacred Heart Medical Center and Children's Hospital — Spokane, Washington
- Mary Bridge Children's Hospital and Health Center — Tacoma, Washington
- Madigan Army Medical Center — Tacoma, Washington
Phase 3 Recruiting Network
This phase III trial tests two hypotheses in patients with low-risk and average-risk medulloblastoma. Medulloblastoma is a type of cancer that occurs in the back of the brain. The term, risk, refers to the chance of the cancer coming back …
Sponsor: Children's Oncology Group
NCT ID: NCT05382338
Sites in Washington: - Seattle Children's Hospital — Seattle, Washington
- Providence Sacred Heart Medical Center and Children's Hospital — Spokane, Washington
- Mary Bridge Children's Hospital and Health Center — Tacoma, Washington
Phase 2, Phase 3 Recruiting Academic/Other
Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and …
Sponsor: Global Coalition for Adaptive Research
NCT ID: NCT03970447
Sites in Washington: - University of Washington Medical Center — Seattle, Washington
Phase 2 Recruiting Network
This phase II trial compares the effect of encorafenib, binimetinib, and nivolumab versus ipilimumab and nivolumab in treating patients with BRAF- V600 mutant melanoma that has spread to the brain (brain metastases). Encorafenib and binime…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT04511013
Sites in Washington: - Providence Regional Cancer System-Aberdeen — Aberdeen, Washington
- PeaceHealth Saint Joseph Medical Center — Bellingham, Washington
- Providence Regional Cancer System-Centralia — Centralia, Washington
- Swedish Cancer Institute-Edmonds — Edmonds, Washington
- Providence Regional Cancer Partnership — Everett, Washington
Phase 2 Recruiting Network
This phase II trial studies the best approach to combine chemotherapy and radiation therapy (RT) based on the patient's response to induction chemotherapy in patients with non-germinomatous germ cell tumors (NGGCT) that have not spread to …
Sponsor: Children's Oncology Group
NCT ID: NCT04684368
Sites in Washington: - Seattle Children's Hospital — Seattle, Washington
- Providence Sacred Heart Medical Center and Children's Hospital — Spokane, Washington
- Mary Bridge Children's Hospital and Health Center — Tacoma, Washington
- Madigan Army Medical Center — Tacoma, Washington
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond…
Sponsor: Children's Oncology Group
NCT ID: NCT04870944
Sites in Washington: - Seattle Children's Hospital — Seattle, Washington
Phase 2 Recruiting Industry
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive primary ce…
Sponsor: Fore Biotherapeutics
NCT ID: NCT05503797
Sites in Washington: - University of Washington School of Medicine — Seattle, Washington
Phase 2 Recruiting Industry
This is an open-label, multicenter Phase 2 study evaluating BMS-986504 in participants with advanced and/or metastatic solid tumors that have MTAP deletion. The study includes a monotherapy component and a combination component in which BM…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07492680
Sites in Washington: - Local Institution - 0086 — Seattle, Washington
Phase 2 Recruiting Academic/Other
This study will address the question of whether targeting CMV antigens with PEP-CMV can serve as a novel immunotherapeutic approach in pediatric patients with newly-diagnosed high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIP…
Sponsor: Nationwide Children's Hospital
NCT ID: NCT05096481
Sites in Washington: - Seattle Children's Hospital — Seattle, Washington
Phase 2 Recruiting Academic/Other
This is a Phase II open-label study to investigate the safety and efficacy of ACT001 in patients with DIPG and H3K27-altered HGG.
Sponsor: Nationwide Children's Hospital
NCT ID: NCT06838676
Sites in Washington: - Seattle Children's Hospital — Seattle, Washington
Phase 2 Recruiting Academic/Other
The goal of this study is to determine the efficacy of the 1) ribociclib and everolimus to treat pediatric and young adult patients newly diagnosed with a high-grade glioma (HGG), including DIPG, that have genetic changes in pathways (cell…
Sponsor: Nationwide Children's Hospital
NCT ID: NCT05843253
Sites in Washington: - Seattle Children's Hospital — Seattle, Washington
Phase 2 Recruiting Industry
The goal of this study is to determine the efficacy of the study drug olutasidenib to treat newly diagnosed pediatric and young adult patients with a high-grade glioma (HGG) harboring an IDH1 mutation. The main question the study aims to a…
Sponsor: Rigel Pharmaceuticals
NCT ID: NCT06161974
Sites in Washington: - Seattle Children's Hospital — Seattle, Washington
Phase 1, Phase 2 Recruiting Industry
The primary purpose of the Phase 1 (Dose Escalation) of this study is to identify the dose-limiting toxicities (DLTs) of Debio 0123 combined with temozolomide (TMZ) (Arm A) and with TMZ and radiotherapy (RT) (Arms B and C) and to character…
Sponsor: Debiopharm International SA
NCT ID: NCT05765812
Sites in Washington: - Fred Hutchinson Cancer Research Center — Seattle, Washington
Phase 1, Phase 2 Recruiting Industry
This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the treatment of patients with radiographically-confirmed progression of…
Sponsor: Neonc Technologies, Inc.
NCT ID: NCT06047379
Sites in Washington: - Northwest Medical Specialties — Tacoma, Washington
Phase 2 Recruiting Industry
This study will evaluate BCB-276, an investigational B7-H3-targeted Chimeric Antigen Receptor (CAR) T cell therapy, in children and young adults with diffuse intrinsic pontine glioma (DIPG). DIPG is a rare and aggressive brain tumor with l…
Sponsor: BrainChild Bio, Inc
NCT ID: NCT07680439
Sites in Washington: - Seattle Children's Hospital — Seattle, Washington
Phase 1, Phase 2 Recruiting Academic/Other
Phase I study to examine safety of the addition of concurrent tarlatamab with standard palliative and consolidative RT regimens , with a main cohort of N=20-24 patients with extracranial anatomic radiation sites. I) After lead in of 10 pat…
Sponsor: University of Arizona
NCT ID: NCT06814496
Sites in Washington: - University of Washington Fred Hutchinson Cancer Center — Seattle, Washington
Phase 1, Phase 2 Recruiting Academic/Other
This is a Phase 1/Phase 2 study assessing liothyronine (L-T3) immunotherapy and in combination with standard chemotherapy (bevacizumab, irinotecan and temozolomide (BIT)) in children and young adults with medulloblastoma that is relapsed o…
Sponsor: Sabine Mueller, MD, PhD
NCT ID: NCT07346157
Sites in Washington: - Seattle Children's — Seattle, Washington
Phase 1 Recruiting Industry
This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.
Sponsor: Iambic Therapeutics, Inc
NCT ID: NCT06253871
Sites in Washington: - Fred Hutchinson Cancer Center — Seattle, Washington
EARLY Phase 1 Recruiting Academic/Other
This is a pilot study that will evaluate disease status in children that have been newly diagnosed high-grade glioma with TRK fusion. The evaluation will occur after 2 cycles of the medication (Larotrectinib) have been given. The study wil…
Sponsor: Nationwide Children's Hospital
NCT ID: NCT04655404
Sites in Washington: - Seattle Children's Hospital — Seattle, Washington
EARLY Phase 1 Recruiting Academic/Other
The goal of this study is to determine the response of the study drug loratinib in treating children who are newly diagnosed high-grade glioma with a fusion in ALK or ROS1. It will also evaluate the safety of lorlatinib when given with che…
Sponsor: Nationwide Children's Hospital
NCT ID: NCT06333899
Sites in Washington: - Seattle Children's Hospital — Seattle, Washington
EARLY Phase 1 Recruiting Academic/Other
Proposed treatment of subjects with newly diagnosed glioblastoma with novel personalized drug regimens identified to be effective in vitro using cancer stem cells derived from their individual tumors, alongside standard of care radiation a…
Sponsor: Swedish Medical Center
NCT ID: NCT05380349
Sites in Washington: - Swedish Medical Center — Seattle, Washington
Phase 1 Recruiting Academic/Other
This is a Phase 1 study of central nervous system (CNS) locoregional adoptive therapy with autologous CD4+ and CD8+ T cells lentivirally transduced to express a B7H3-specific chimeric antigen receptor (CAR) and EGFRt. CAR T cells are deliv…
Sponsor: Seattle Children's Hospital
NCT ID: NCT04185038
Sites in Washington: - Seattle Children's Hospital — Seattle, Washington
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Washington: - Massive Bio SYNERGY-AI site — Seattle, Washington